News

Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.

Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.

The assessment of circulating tumor cells in peripheral blood outperformed quantification of bone marrow plasma cells and the discovery of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible...

Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...

Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...

Researchers provided evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non–small-cell lung cancer without driver alterations.

Patients with newly diagnosed multiple myeloma treated with combination regimen of bortezomib, lenalidomide, and dexamethasone induction followed by early autologous stem cell transplantation (ASCT) may not have a greater occurrence of...

Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.

A recent study assessed the combined impact of Medicare’s pay for performance (P4P) programs on clinical areas and populations targeted by the programs, as well as those outside their focus, and found that minimal, if any, effect of...

A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.